Cosmo Pharmaceuticals N.V. Stock

Equities

COPN

NL0011832936

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:41 2024-05-31 am EDT 5-day change 1st Jan Change
70.8 CHF +0.43% Intraday chart for Cosmo Pharmaceuticals N.V. -0.98% +39.10%

Financials

Sales 2023 96.72M 105M 94.63M Sales 2024 * 262M 284M 256M Capitalization 1.16B 1.26B 1.13B
Net income 2023 1M 1.08M 978K Net income 2024 * 111M 120M 109M EV / Sales 2023 8.6 x
Net cash position 2023 48.44M 52.53M 47.39M Net cash position 2024 * 110M 119M 108M EV / Sales 2024 * 4.01 x
P/E ratio 2023
771 x
P/E ratio 2024 *
9.93 x
Employees 319
Yield 2023
3.65%
Yield 2024 *
2.91%
Free-Float 44.36%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Cosmo Pharmaceuticals N.V.

1 day+0.43%
1 week-0.98%
1 month-2.07%
3 months+7.44%
6 months+64.65%
Current year+39.10%
More quotes
1 week
69.40
Extreme 69.4
73.40
1 month
69.40
Extreme 69.4
74.50
Current year
51.20
Extreme 51.2
76.00
1 year
33.70
Extreme 33.7
76.00
3 years
33.70
Extreme 33.7
90.10
5 years
33.70
Extreme 33.7
99.80
10 years
33.70
Extreme 33.7
193.70
More quotes
Managers TitleAgeSince
Director of Finance/CFO 52 16-05-31
Chairman 61 05-12-31
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Founder 69 96-12-31
Director/Board Member 69 12-03-31
Chairman 61 05-12-31
More insiders
Date Price Change Volume
24-05-31 70.8 +0.43% 26,123
24-05-30 70.5 -0.70% 12,986
24-05-29 71 -0.28% 9,891
24-05-28 71.2 -1.39% 12,392
24-05-27 72.2 +0.98% 5,555

Delayed Quote Swiss Exchange, May 31, 2024 at 11:30 am EDT

More quotes
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
72.26 EUR
Average target price
94.95 EUR
Spread / Average Target
+31.41%
Consensus